Pall Life Sciences to introduce continuous bioprocessing with single-use technologies

Will enable manufacturers to reduce costs by eliminating cleaning and validation requirements, as well as hardware infrastructure.

As manufacturers of biotherapies seek to incorporate continuous technologies in production to improve efficiency over batch methods, and to enable process intensification, Pall is forging ahead by offering biopharmaceutical companies an “end-to-end” continuous processing option with integrated single-use technologies. Single-use systems enable manufacturers to reduce costs by eliminating cleaning and validation requirements, as well as hardware infrastructure.

Last year Pall introduced the Cadence BioSMB PD System, the first disposable flow path, continuous multi-column chromatography system that is scalable from laboratory process development to GMP manufacturing. Earlier this year, Pall introduced the Cadence Acoustic Separator (CAS)1, a groundbreaking invention that incorporates acoustic wave separation (AWS) technology to continuously harvest biologic drug substances from cell culture processes. At BPI Pall will continue to advance its pipeline of products that enable continuous manufacturing by launching production-scale continuous chromatography solutions, a new single-use stirred tank bioreactor, single-use sterile genderless connectors, and other equipment and materials. In addition, Pall will feature filtration technology for consistent and robust small virus retention.

“At Pall we are helping the industry move continuous bioprocessing from theory to reality,” said Michael Egholm, VP and General Manager, Pall BioPharmaceuticals. “Our continuous-ready products and integration expertise help manufacturers of biotherapeutics achieve high-quality products with smaller production footprints and shorter lead times.”